SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

Company limited by guarantee

Company Registration Number:
03575079 (England and Wales)

Unaudited statutory accounts for the year ended 31 March 2025

Period of accounts

Start date: 1 April 2024

End date: 31 March 2025

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

Contents of the Financial Statements

for the Period Ended 31 March 2025

Directors report
Profit and loss
Balance sheet
Additional notes
Balance sheet notes

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

Directors' report period ended 31 March 2025

The directors present their report with the financial statements of the company for the period ended 31 March 2025

Principal activities of the company

The principal Charitable activities of the company in the year under review were those lo provide relief of poverty, sickness and distress, and enhancement of life, to those affected by the disorders Sickle Cell Disease and Thalassaemia, living within the West Midlands and surrounding areas. Those so affected are predominantly from African, Caribbean, Mediterranean and Asian communities. In 2016 the charily had expanded its activities lo include working with families with complex and multiple needs, in order to promote, strengthen and Improve their life chances.



Directors

The directors shown below have held office during the whole of the period from
1 April 2024 to 31 March 2025

Clarence Crosdale
Linton Bell
Donald Mcintosh
Dr Deepak Kalra
Anita Ezomon
Loury Mooruth
Diana Smith
Dorothy McIntosh


Secretary Sutinder Herian

The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
23 September 2025

And signed on behalf of the board by:
Name: Clarence Crosdale
Status: Director

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

Profit And Loss Account

for the Period Ended 31 March 2025

2025 2024


£

£
Turnover: 261,520 292,049
Cost of sales: 0 0
Gross profit(or loss): 261,520 292,049
Operating profit(or loss): 261,520 292,049
Profit(or loss) before tax: 261,520 292,049
Profit(or loss) for the financial year: 261,520 292,049

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

Balance sheet

As at 31 March 2025

Notes 2025 2024


£

£
Fixed assets
Tangible assets: 3 428 504
Total fixed assets: 428 504
Current assets
Debtors: 4 12,910 7,190
Cash at bank and in hand: 729,567 760,334
Investments: 5 54,796 52,924
Total current assets: 797,273 820,448
Creditors: amounts falling due within one year: 6 ( 1,550 ) ( 2,840 )
Net current assets (liabilities): 795,723 817,608
Total assets less current liabilities: 796,151 818,112
Creditors: amounts falling due after more than one year: 7 ( 85,000 ) ( 85,000 )
Total net assets (liabilities): 711,151 733,112
Members' funds
Profit and loss account: 711,151 733,112
Total members' funds: 711,151 733,112

The notes form part of these financial statements

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

Balance sheet statements

For the year ending 31 March 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 23 September 2025
and signed on behalf of the board by:

Name: Linton Bell
Status: Director

The notes form part of these financial statements

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

Notes to the Financial Statements

for the Period Ended 31 March 2025

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

    Tangible fixed assets depreciation policy

    Tangible fixed assets are inltially measured at cost and subsequently measured at cost or valuation. net of depreciation and any impairment losses. Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases: Plant and machinery Fixtures and fittings -25%oncost - 15% & 25% on reducing balance The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset. and is recognised in the statement of financial activities.

    Other accounting policies

    All expenditure is accounted for on an accruals basis and has been Classified under headings that aggregate all costs related to the category. Where costs cannot by directly attributed to particular headings they have been allocated to activities on a basis consistent with use of the resources. Fund-raising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities. Support costs are costs incurred directly in support or expenditure on the objects or the charity and include project management carried out at headquarters. Management and administration costs are those incurred in connection with the administration of the charity and compliance with constitutional and statutory requirements.

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

Notes to the Financial Statements

for the Period Ended 31 March 2025

  • 2. Employees

    2025 2024
    Average number of employees during the period 5 5

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

Notes to the Financial Statements

for the Period Ended 31 March 2025

3. Tangible assets

Land & buildings Plant & machinery Fixtures & fittings Office equipment Motor vehicles Total
Cost £ £ £ £ £ £
At 1 April 2024 0 23,824 13,391 0 0 37,215
Additions 0 0 0 0 0 0
Disposals 0 0 0 0 0 0
Revaluations
Transfers
At 31 March 2025 0 23,824 13,391 0 0 37,215
Depreciation
At 1 April 2024 23,824 12,887 36,711
Charge for year 0 76 76
On disposals
Other adjustments
At 31 March 2025 23,824 12,963 36,787
Net book value
At 31 March 2025 0 0 428 0 0 428
At 31 March 2024 0 0 504 0 0 504

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

Notes to the Financial Statements

for the Period Ended 31 March 2025

4. Debtors

2025 2024
£ £
Prepayments and accrued income 12,910 7,190
Total 12,910 7,190

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

Notes to the Financial Statements

for the Period Ended 31 March 2025

5. Current assets investments note

N/A

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

Notes to the Financial Statements

for the Period Ended 31 March 2025

6. Creditors: amounts falling due within one year note

2025 2024
£ £
Accruals and deferred income 1,550 2,840
Total 1,550 2,840

SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

Notes to the Financial Statements

for the Period Ended 31 March 2025

7. Creditors: amounts falling due after more than one year note

2025 2024
£ £
Other creditors 85,000 85,000
Total 85,000 85,000